61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Halozyme Therapeutics Inc
Closed
Sector Healthcare
56.48 0.32
Overview
Share price change
24h
Min
56.03
Max
57.37
Income | 44M 137M |
|---|---|
Sales | 59M 290M |
P/E Sector Avg | 15.821 59.362 |
EPS | 1.27 |
Profit margin | 47.245 |
EBITDA | 41M 184M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +11.74 upside |
Next Earnings | 18 Feb 2025 |
|---|
Market Cap | 243M 7.2B |
|---|---|
Previous open | 56.16 |
Previous close | 56.48 |
News Sentiment
By Acuity
21%
79%
41 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
Halozyme Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Halozyme Therapeutics Inc Forecast
Price Target
By TipRanks
11.74% upside
12 Months Forecast
Average 63.29 USD 11.74%
High 77 USD
Low 53 USD
Based on 7 Wall Street analysts offering 12 month price targets forHalozyme Therapeutics Inc - Dist in the last 3 months.
Sentiment
By Acuity
41 / 393 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc. is a biopharma technology platform company. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE drug delivery technology with the collaborators' compounds. The Company's lead enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. The Company's approved product and its collaborators’ approved products and product candidates are based on rHuPH20, a patented recombinant human hyaluronidase enzyme. The Company's lead product, Hylenex recombinant, is a formulation of rHuPH20 that facilitates subcutaneous fluid administration for achieving hydration, to increase the dispersion and absorption of other injected drugs and, in subcutaneous urography, to improve resorption of radiopaque agents. Its pipeline products include Herceptin SC, HYQVIA, DARZALEX and others.
